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ABSTRACT 
The Marfan syndrome (MFS) is strongly associated with aortic disease causing a high 
prevalence of prophylactic aortic surgery, aortic dissection, and sudden death. The aim of the 
present study was to evaluate mortality in a nationwide Danish MFS population diagnosed 
by the Ghent II criteria. In a register-based setting, we identified all Danish patients with 
MFS (n=412, male n=215) by assessment of their medical records. We established a gender 
and age matched control cohort based on 41,000 control persons (male n=21,500). MFS 
cases risk time was 6,669 persons years. We applied Cox regression using each case and 
his/her control as one stratum, adjusting for age and calendar time. We found a significantly 
decreased lifespan of 50 years compared to 60 years among controls. The mortality hazard 
ratio (HR) among MFS compared to controls was significantly increased to 3.6 (CI 2.8–4.7, 
p<0.001); males 4.0 (CI 2.8–5.7, p<0.001); females 3.2 (CI 2.1-4.8, p<0.001). Aorta disease 
represented the main reason for the overall increased mortality with a HR of 194.6 (CI 67.4-
561.7, p<0.0001); males 208.7 (CI 53.8–809.1, p<0.001); females 173.4 (CI 31.5–954.5, 
p<0.001). In addition, an unexplained mortality due to respiratory illness was not attributed 
to pneumothorax. Excluding cardiovascular and respiratory causes of death, we found no 
indication that MFS is associated with increased mortality for other reasons. 
 
Key words 
Epidemiology, rare diseases, aortic aneurism, aortic dissection, sudden death 
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BACKGROUND 
Marfan syndrome (MFS) is a dominant hereditary connective tissue disease with a 
prevalence of 6.5/100,000
1
. It is a multiorgan disease affecting the spine, the musculoskeletal 
system, the eyes and lungs. Among the many phenotypic traits of MFS, aortic disease is the 
most detrimental, causing a high prevalence of early aortic events of both prophylactic 
surgery and aortic dissection
2
. It is not clear how high the mortality rates are in MFS. The 
latest survival study in MFS done by Silverman et al., used older diagnostic criteria and was 
published more than 20 years ago, but reported a mean age of death of only 41 years
3
, 
possibly driven partly by a young cohort of MFS patients. Assumptions are a better survival 
today, supported by the very low mortality from aortic events observed in MFS patients if 
managed according to guidelines in a specialist center
4
. However, in real life MFS patients 
are still diagnosed late and not all patients achieve specialist care before they develop aortic 
disease, so unfortunately a post aortic dissection diagnose is not a rare phnomenon
1,2
. The 
aim of the present study was to evaluate mortality rates in a nationwide Danish MFS 
population diagnosed by the Ghent II criteria. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Page 4 
 
 
 
METHODS 
We retrieved unique personal identification numbers (id-numbers) from all persons 
recorded in either The Danish National Patient Registry (DNPR) 
5
 or The Cause of Death 
Register (CDR) 
6
 with the ICD-10 diagnosis Q87.4 “Marfan Syndrome” or ICD-8 759.80 
“Arachnodactylia (Syndroma Marfan)” during 1977 to 2014 and evaluated all medical 
records as described in a previous study 
1
. In total, we identified 412 persons (215 men) with 
MFS, diagnosed according to the Ghent II criteria. 
 In Denmark, there is a central authority on national statistics. For each MFS patient 
we provided the id-number and the individual date of the MFS diagnosis. Statistics Denmark 
built a control cohort based on 100 individuals per MFS patient matched on sex, birth year 
and the residing municipality. Further, all controls were alive on the date their relevant MFS 
patient was diagnosed. For each patient and his or her controls, time at risk started the year 
of diagnosis. Time at risk ended on the last date of the study period (by end of 2016), first 
date of emigration or on date of death, which ever came first. 
The study was approved by the Scientific Ethical Committee (31422) and the Danish 
Data Protection Agency (2011-41-6986). We retrieved data on date of death until the end of 
2016 and registered 1819 deaths (58 cases and 1761 controls). We retrieved data on causes 
of death on 1612 controls and 51 cases until the end of 2016. Causes of death was not 
registered for 7 deceased cases and 149 deceased controls mainly due to reporting delay for 
2016 deaths (7 cases and 134 controls). We sorted causes of death according to the ICD 10-
chapter system. ICD 8 codes were translated into ICD 10 codes (supplementary table S1). 
Age was not normal distributed and median values are presented. Risk time started at 
year of diagnosis and ended at year of death or at year of other censoring, whichever came 
first. Kaplan-Meier estimates were constructed for mortality. Hazard ratios (HR) and p-
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values were calculated using Cox regression, where each patient and his or her matched 
controls were a stratum, hereby adjusting for gender, age and calendar timer. P values lower 
than 0.05 were considered statistically significant. Stata 12.1 for Windows (StataCorp LP, 
College Station, TX, USA) was used for all calculations. 
RESULTS 
Previously, we identified 412 MFS patients in Denmark (male n=215) 
1
. Two female 
case patients were discarded from the cohort as we were unable to match 100 control persons 
to these cases. We established a control cohort based on 41,000 control persons. We 
identified 352 living cases and 58 diseased cases. In the control group, we identified 39,239 
alive and 1,761 were deceased (Table 1). Median age of living cases by the end of 2016 was 
38.5 years and for controls 40.0 years. The risk time for the MFS cases was 6,669 person 
years. 
The annual death rate for MFS cases was 0.0087 deaths/year/person and for controls 
0.0025 deaths/year/person. The median age at diagnosis was 38.5 years for deceased (range 
0 to 75) and median age at death was 50 years for MFS cases (range 0 to 85 years) and 60 
years (range 1 to 91 years) for controls. The difference in median age at death was 8 years 
for men (MFS cases 50 years (range 3 to 80) and controls 58 years (range 1 to 90)) and 13 
years in women (MFS cases 50 years (range 0 to 85) and controls 63 years (range 1 to 91)). 
We found a significantly increased mortality HR of 3.6 (CI 2.8 – 4.7, p<0.001) (Figure 1); 
male 4.0 (CI 2.8 – 5.7, p<0.001); female 3.2 (CI 2.1-4.8, p<0.001) (Figure 2) among MFS 
compared to controls. Mortality due to cardiovascular diagnoses was significantly increased 
with a HR of 7.0 (CI 4.3-11.6, p<0.001); male 7.0 (CI 3.5 – 13.8, p<0.001), female 7.1 (CI 
3.5 – 14.7, p<0.001). Eleven out of 17 cases with a primary cause of death due to 
cardiovascular disease died from aortic disease (ICD 10 codes I710-I719, ICD 8 codes 4410-
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4412) compared to 6 out of 252 controls. MFS had a HR of 194.6 (CI 67.4-561.7, p<0.000); 
male 208.7 (CI 53.8 – 809.1, p<0.001); female MFS HR of 173.4 (CI 31.5 – 954.5, p<0.001) 
of dying from aortic disease. Except for abdominal dissection the location of the aortic 
disease was not specified (Cases ICD 10 codes: I710 (n=6), I711 (n=2), I718 (n=1), I719 
(n=1), I713 (n=1). Controls ICD 10 codes: I710 (n=1), I713 (n=5)). Sub-analyzing this 
chapter, we found three female cases who died of non-aortic causes (heart failure (n=2) and 
AMI (n=1)) while all male cases died of aorta related causes. Furthermore, fourteen MFS 
cases were registered with a primary cause of death in the congenital chapter (ICD 10 Q874 
or ICD 8 7598). Of these 14 cases, five cases were registered with another secondary code of 
aortic disease. 
Only five controls were registered with a congenital cause of death and none had any 
registration with MFS or cause of death indicating aortic disease. Analyzing both primary 
and secondary causes of death from aortic disease we found 20 cases (11 primary cause of 
death) and 10 controls (6 primary cause of death) with aortic disease, which resulted in a HR 
of 223.7 (CI 98.4-508.9, p<0.001). When evaluating other diagnostic chapters than 
“Circulatory” only “Blood/immunology”, “Respiratory”, “Congenital” and “Other” stands 
out with significantly increased mortality rates among MFS. The Blood/Immunology chapter 
data is based on one case event and can be considered a chance finding (table 2). None of the 
7 cases with a primary respiratory cause of death had pneumothorax as a cause of death 
(primary or secondary causes of death). Among controls, only one died of a pneumothorax. 
The number of cases (n=7) within the respiratory chapter is low and we did not find a pattern 
of causes of death in these cases indicating an explanation of the increased HR (among cases 
ICD 10 code: (n=2) “J960- Acute respiratory failure”, (n=1) “J969 - Respiratory failure, 
unspecified”, (n=1) “J158 - Pneumonia due to other specified bacteria”, (n=1) “J151 - 
Pneumonia due to Pseudomonas”, (n=1) “J189 - Pneumonia, unspecified organism”, (n=1) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Page 7 
 
 
 
“J690 - Pneumonitis due to inhalation of food and vomit”). The increased HR in the 
congenital chapter was solely based on the MFS diagnosis among the cases as all 14 cases 
are registered with MFS as primary cause of death. A rather large proportion (5/14, 36%) 
had aortic disease as secondary cause of death and another five cases had other vascular 
secondary causes of death (“K55.0 Acute vascular disorder in the intestine”, “I35.9 Aortic 
Valve Disorder, unspecified”, “I69.4 Sequelae of stroke, not specified as hemorrhage or 
infarction”, “Z95.2 Presence of prosthetic heart valve”, “746.9 Unspecified anomalies of 
heart”) while four were solely registered with MFS as the primary cause of death. 
The “Other” chapter include “ill-defined and unknown causes of mortality”. Among 
the 6 cases in this chapter two were “R989 - Unattended death” as primary cause of death 
and the secondary cause was “Q874 – Marfan Syndrome”. Two cases were registered as 
“R092 – Respiratory arrest” and “Q874 – Marfan syndrome” as a secondary cause. One was 
“R99.1 - Other ill-defined and unspecified causes of mortality” as primary cause of death 
and secondary cause “Q874 – Marfan Syndrome”. One was “R57.0 – Cardiogenic shock”. 
No autopsy was performed in any of the six cases and all cases were registered as a death 
caused by “Natural causes”. A speculative guess could be that the overrepresentation could 
be due to aortic rupture causing registration as sudden unattended death. Merging all ICD 
chapters except the circulatory chapter showed a non-significant mortality HR of 1.1 (CI 
0.97 – 1.19, P=0.156) indicating that circulatory causes are the main reason for deaths 
among MFS. 
DISCUSSION 
Our study clearly indicates that the MFS diagnosis is associated with a significant 
increased all-cause mortality hazard ratio for both men and women at any time in life 
compared to the normal population. As expected, cardiovascular causes of death were the 
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major contributor with an overwhelming seven-fold increased HR and with an almost two 
hundred-fold increased HR of dying from aortic disease.  
This study also shows that having MFS results in median age at death of 50 years. In 
the study by Silverman et al. the mean age at death was only 41 years, however, since there 
were no data on the age of the total cohort in Silverman’s study, we cannot compare these 
two studies directly. Nevertheless, MFS cases still have a reduced median age at death of 8 
to 13 years compared to the background population. Men and women had a similar lifespan 
which is in contradiction to previous studies that have shown that males with MFS are more 
likely to develop aortic disease including both prophylactic surgery and dissections
2,7
.  
In the present study, more than half of the MFS patients were not diagnosed until adult 
life
1
. In addition, a substantial part of MFS patients may also have died undiagnosed and are 
therefore not included in the present cohort. For the same reason, many patients were not 
diagnosed until after they had aortic dissection, which creates a much poorer outcome
2
. 
Therefore, it must be emphasized that identification of patients with MFS as early as 
possible is essential to provide the best possible care. An additional advance will be to 
identify MFS patients with a high risk of aortic dissection. A recent study indicated that 
MFS patients with aortic stiffness may have a higher risk of aortic dilatation and dissection 
which could mean that a subset of MFS patients should be followed more closely or have 
surgery at an earlier stage
8
. Until now, preventive pharmacological treatment has not shown 
a dramatic effect in preventing aortic dilatation and dissection
9,10
 and it is still uncertain if 
any existing drug can do this
11
. It is difficult to argue convincingly either for the 
mechanobiological effects of betablockers or for inhibition of the TGFβ-system with 
Losartan
12
. Instead it seems that specialized follow-up and timely aortic surgery by dedicated 
surgical teams seem to be the most important factor for long-term survival
4
. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Page 9 
 
 
 
The recommended aortic size limit is 5 cm and there is no evidence to support that 
aortic root replacement at smaller aortic diameters improves survival. However, there are 
specialized recommendations for women and pregnancy, where prophylactic surgery should 
be offered at 4.5 cm if the woman with MFS wishes to be pregnant
13
. We were unable to find 
any evidence in our data that indicated that pregnancy included a significantly increased 
mortality risk in this cohort, which is in contrast to previous observations
14
.  
Altered fluid hemodynamics after aortic root replacement
15
 may be one among many 
reasons why MFS patients experience type B dissections late after prophylactic aortic root 
surgery
16
. It is therefore important also to observe the aortic arch and descending aorta 
meticulously when doing post-surgery follow-ups and offer treatment in due course
7
. 
Another major issue is reconstructive aortic surgery in MFS patients with chronic 
dissections
17
. Even though results seem excellent in highly specialized high-volume centers
18
 
the reality is that thoracoabdominal aortic repair of chronic dissections is a high-risk 
procedure also with considerable morbidity risk including spinal cord injury
19
. 
Our data do not indicate that MFS individuals present a higher risk of death by other 
causes of death than cardio vascular. As mitral valve prolapse is a common phenotypic 
manifestation in MFS
7
 we expected to find an overrepresentation of mitral disease among 
cases. However, we did not find a single case with mitral disease as the primary cause of 
death indicating that mitral valve disease may be common but not fatal.  
We assumed that pneumothorax would be the main cause of case representation in the 
“Respiratory” chapter. However, it is noteworthy that none of the cases with a respiratory 
cause of death had pneumothorax as a cause of death. We have no explanation of the 
overrepresentation of respiratory causes of death. An explanation could be respiratory 
complication in relation to aortic surgery. Obstructive sleep apnea is another major issue in 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Page 10 
 
 
 
MFS but since this disorder is not registered systematically in Denmark, due to most 
treatment is managed in private hospital settings we cannot give an estimate of the influence 
from sleep apnea. 
There are some limitations and possible bias due to the case-control study design. It is 
likely that we primarily included case patients with an obvious phenotype, and we cannot 
exclude that some cases are not yet diagnosed or have already died without being diagnosed. 
For these reasons, we may have overestimated the event rate. Diagnostic criteria for MFS 
have changed several times over the years but we recently showed that implementation new 
criteria 
20-22
 did not have a large impact on incidence and prevalence of MFS 
1
. 
In conclusion, MFS has significantly increased overall mortality driven by death due to 
aortic disease with a HR of almost 200. In addition, an unexplained mortality due to 
respiratory illness was also observed. When excluding cardiovascular and respiratory causes 
of death, we found no indication that MFS is associated with increased mortality for other 
reasons. 
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Figure 1: Kaplan-Meier survival curves for cases and controls with 95% confidence intervals. Time 
starts at diagnosis of case patient. 
Figure 2: Kaplan-Meier survival curves for cases and controls divided on gender. Time starts at 
diagnosis of case patient.  
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Table 1 
Data on cases and controls. 
 Total cohort Male Female 
Cases (MFS) 410 215 (52%) 195 (48%) 
Cases alive 352 182 (52%) 170 (48%) 
Cases diseased 58 33 (57%) 25 (43%) 
Controls 41,000 21,500 (52%) 19,500 (48%) 
Controls alive 39,239 20,504 (52%) 18,735 (48%) 
Controls diseased 1,761 996 (57%) 765 (43%) 
 
Table 2 
Cause of death data divided by ICD chapter. HR: hazard ratio of death case compared with 
controls. Data only on causes of death data. 
 Cases Control HR Confidence 
interval 
p-value 
Combined 51 1612 3.4 2.6-4.5 <0.001 
Infection 0 70 - - - 
Neoplasm 3 390 0.8 0.3-2.6 0.771 
Blood/ immunology 1 3 31.9 2.6-387.5 0.007 
Endocrine 0 30 - - - 
Mental 0 26 - - - 
CNS 0 22 - - - 
Eyes 0 0 - - - 
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Ears 0 0 - - - 
Circulatory 17 252 7.0 4.3-11.6 <0.001 
Respiratory 7 246 3.0 1.4-6.3 0.005 
Digestive 0 82 - - - 
Skin 0 0 - - - 
Musculoskeletal 0 2 - - - 
Genitourinary 0 14 - - - 
Pregnancy 0 0 - - - 
Perinatal 0 0 - - - 
Congenital 14 5 274.8 99.0-763.2 <0.001 
Other 6 265 2.4 1.1-5.5 0.031 
Injury, poisoning & external 3 205 1.6 0.5-5.0 0.427 
Unknown cause (no data) 7 134    
“-“: HR’s could not be calculated. 
 
 
